BIOS - BioScrip, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.1100
+0.0500 (+2.43%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.0600
Open2.0500
Bid2.1100 x 800
Ask2.1600 x 21500
Day's Range2.0500 - 2.1900
52 Week Range1.5600 - 4.1400
Volume1,007,171
Avg. Volume1,684,317
Market Cap271.679M
Beta (3Y Monthly)0.12
PE Ratio (TTM)N/A
EPS (TTM)-0.5230
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.79
Trade prices are not sourced from all markets
  • Moody's5 days ago

    BioScrip, Inc. -- Moody's upgrades BioScrip, Inc.'s Corporate Family Rating to B3, outlook stable

    Moody's Investors Service ("Moody's") today upgraded the Corporate Family Rating (CFR) of BioScrip, Inc. ("BioScrip") to B3 from Caa1 and upgraded the Probability of Default to B3-PD from Caa1-PD. At the same time, Moody's upgraded the Speculative Grade Liquidity Rating to SGL-3 from SGL-4 and assigned a B2 (LGD 3) rating to the proposed $925 million First Lien Term Loan B. The outlook is stable. The upgrade reflects the improvement in BioScrip's credit profile due to the pending merger with HC Group Holdings III, Inc. (dba Option Care).

  • Here’s What Hedge Funds Think About BioScrip Inc. (BIOS)
    Insider Monkey10 days ago

    Here’s What Hedge Funds Think About BioScrip Inc. (BIOS)

    The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the fourth quarter, which unveil their equity positions as of December 31. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]

  • BioScrip's Option Care Merger on Track, Q1 Loss Narrows
    Zacks11 days ago

    BioScrip's Option Care Merger on Track, Q1 Loss Narrows

    BioScrip (BIOS) is highly upbeat about the strategic and financial virtues of Option Care consolidation.

  • GlobeNewswire17 days ago

    MERGER INVESTIGATION NOTICE: Kaskela Law LLC Announces Shareholder Investigation of BioScrip, Inc. – BIOS

    NEWTOWN SQUARE, Pa., May 03, 2019 -- Kaskela Law LLC announces that it is investigating BioScrip, Inc. (“BioScrip” or the “Company”) (Nasdaq: BIOS) on behalf of the Company’s.

  • BioScrip (BIOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
    Zacks18 days ago

    BioScrip (BIOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    BioScrip (BIOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • BioScrip (BIOS) Reports Q1 Loss, Tops Revenue Estimates
    Zacks18 days ago

    BioScrip (BIOS) Reports Q1 Loss, Tops Revenue Estimates

    BioScrip (BIOS) delivered earnings and revenue surprises of 16.67% and 0.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press18 days ago

    BioScrip: 1Q Earnings Snapshot

    On a per-share basis, the Denver-based company said it had a loss of 10 cents. The infusion and home care services company posted revenue of $179 million in the period. The company's shares closed at $1.90. ...

  • GlobeNewswire18 days ago

    BioScrip Reports First Quarter 2019 Financial Results

    DENVER, May 02, 2019 -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions,.

  • GlobeNewswire27 days ago

    BioScrip, Inc. Provides Merger Update

    BioScrip, Inc. (BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today provided an update on its proposed merger with Option Care Enterprises, Inc. (“Option Care”). The Company expects to file the preliminary Option Care merger proxy statement the week of April 29, 2019 with the U.S. Securities and Exchange Commission (“SEC”).  After the proxy statement is filed, management from both BioScrip and Option Care plan to conduct joint analyst and investor meetings.  As part of the analyst and investor meetings, the Company will file an investor presentation with the SEC that will include a business and merger update.

  • Moody'slast month

    HC Group Holdings III, Inc. -- Moody's announces completion of a periodic review of ratings of HC Group Holdings III, Inc.

    Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of HC Group Holdings III, Inc. New York, April 18, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of HC Group Holdings III, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • Moving Average Crossover Alert: BioScrip
    Zackslast month

    Moving Average Crossover Alert: BioScrip

    BioScrip, Inc. (BIOS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

  • Why Is BioScrip (BIOS) Down 50.4% Since Last Earnings Report?
    Zackslast month

    Why Is BioScrip (BIOS) Down 50.4% Since Last Earnings Report?

    BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • New Strong Sell Stocks for April 11th
    Zackslast month

    New Strong Sell Stocks for April 11th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.

  • New Strong Sell Stocks for April 9th
    Zackslast month

    New Strong Sell Stocks for April 9th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of BIOS earnings conference call or presentation 15-Mar-19 1:00pm GMT

    Q4 2018 BioScrip Inc Earnings and Definitive Merger Agreement with Option Care Call

  • Moody's2 months ago

    BioScrip, Inc. -- Moody's places BioScrip's ratings under review for upgrade following the announced merger with HC Group Holdings

    Moody's Investors Service ("Moody's") today placed the ratings of BioScrip, Inc. (BioScrip), including the Caa1 Corporate Family Rating (CFR), under review for upgrade. This follows the announcement that BioScrip will merge with HC Group Holdings III, Inc.(dba Option Care). BioScrip will issue common stock to Option Care in an all-stock deal.

  • MarketWatch2 months ago

    BioScrip's stock extends plunge after merger terms disappoint, but analyst recommends remaining bullish

    Shares of BioScrip Inc. tumbled 9.0% toward a 9-month low in midday trade Monday, extending the sharp reversal suffered early in the previous session as investors digested the terms of the company's merger deal with Option Care Enterprises Inc. On Friday, the stock soared as much as 71% in premarket trade, and as much as 8.0% during the regular session, before pulling a sharp U-turn to close down 20.3%. Canaccord Genuity analyst Richard Close said that investors may have to suffer some short-term pain, given the disappointment that BioScrip shareholders will own just 20% of the post-merger company, but he remains bullish given the long-term potential. "The need for scale in health care is increasingly paramount as the provider and payer markets consolidate and reimbursement risk is always present," Close wrote in a research note. "Thus, having scale is a significant advantage as [BioScrip] seeks to negotiate rates and drive sustained operating results." The stock has tumbled 35.5% year to date, while the S&P 500 has climbed 12.7%.

  • BioScrip (BIOS) Reports Loss in Q4, Both Margins Contract
    Zacks2 months ago

    BioScrip (BIOS) Reports Loss in Q4, Both Margins Contract

    The combined expertise of BioScrip (BIOS) and OptionCare is expected to drive significant growth for the former.

  • Do Options Traders Know Something About BioScrip (BIOS) Stock We Don't?
    Zacks2 months ago

    Do Options Traders Know Something About BioScrip (BIOS) Stock We Don't?

    Investors need to pay close attention to BioScrip (BIOS) stock based on the movements in the options market lately.

  • ACCESSWIRE2 months ago

    Merger Agreement and Earnings Review in this Comprehensive Report on BioScrip

    NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Traders News Source, a leading independent equity researchand corporate access firm focused on small and mid-cap public companies isissuing a comprehensive report on BioScrip Inc. (BIOS), a provider of infusion and home care management solutions, with approximately 2,500 teammates and nearly 80 service locations across the U.S. BioScrip partners with physicians, hospital systems, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. Recently, BioScrip and Option Care jointly announced a definitive merger agreement, which will create the nation's preeminent home infusion company and transform the industry. Option Care's signature Home Infusion Plus services include the clinical management of infusion medicines, nursing support, and care coordination.

  • Why Adobe, BioScrip, and Ascena Retail Group Slumped Today
    Motley Fool2 months ago

    Why Adobe, BioScrip, and Ascena Retail Group Slumped Today

    Earnings and other bad news kept these stocks out of today's rally.

  • Bioscrip Inc (BIOS) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Bioscrip Inc (BIOS) Q4 2018 Earnings Conference Call Transcript

    BIOS earnings call for the period ending December 31, 2018.

  • Why BioScrip Stock Popped and Then Dropped Today
    Motley Fool2 months ago

    Why BioScrip Stock Popped and Then Dropped Today

    BioScrip's fourth-quarter results and merger with Option Care Enterprises aren't sitting well with shareholders.

  • TheStreet.com2 months ago

    Infusion Therapy Firm BioScrip to Buy Rival Option Care

    agreed to buy rival Option Care Enterprises, creating one of the largest independent home-therapy companies in the U.S. On completion of the all-stock deal, MDP funds and WBA will own roughly 80% of the combined publicly traded company on a fully diluted basis, with current BioScrip shareholders holding the remainder, the companies said. Option Care CEO John Rademacher will lead the combined company.

  • MarketWatch2 months ago

    BioScrip's stock soars after merger deal with Option Care, owned by Walgreens and Madison Dearborn

    Shares of BioScrip Inc. soared 32% toward a 4-year high in premarket trade Friday, after the company announced a deal to merge with privately held Option Care Enterprises Inc., a provider of home and alternate treatment site infusion therapy services owned by funds affiliated with Walgreens Boots Alliance Inc. and private-equity firm Madison Dearborn Partners LLC (MDP). BioScrip's stock is halted for news until 7:30 a.m. Eastern. Under terms of the agreement, BioScrip will issue new shares to Option Care's shareholder and Walgreens and MDP will own about 80% of the combined publicly traded company. BioScrip's market capitalization was about $446.9 million as of Thursday's close. "This is a compelling and complementary fit of two leading players in the U.S. infusion market," said BioScrip Chief Executive Daniel Greenleaf. "Together, we will be able to provide a diverse set of life-improving and cost-effective services to more patients across the United States." BioScrip's stock has rallied 31% over the past 12 months, while the SPDR Health Care Select Sector ETF has gained 6.9% and the Dow Jones Industrial Average has tacked on 3.4%.